These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 36016257)

  • 21. Prostate cancer, new treatment advances - immunotherapy.
    Silva D; Abreu-Mendes P; Mourato C; Martins D; Cruz R; Mendes F
    Actas Urol Esp (Engl Ed); 2020 Sep; 44(7):458-468. PubMed ID: 32473820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploiting synergy: immune-based combinations in the treatment of prostate cancer.
    Burotto M; Singh N; Heery CR; Gulley JL; Madan RA
    Front Oncol; 2014; 4():351. PubMed ID: 25566495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
    Lohmueller J; Finn OJ
    Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Landscape of Immunotherapy in Genitourinary Malignancies.
    Alhalabi O; Rafei H; Bilen MA; Shah AY
    Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for advanced gastric cancer.
    Leowattana W; Leowattana P; Leowattana T
    World J Methodol; 2023 Jun; 13(3):79-97. PubMed ID: 37456977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
    Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
    Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Sun BL
    Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
    Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Karapedi E; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Papavassiliou KA; Karamouzis MV; Papavassiliou AG
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
    Xiong W; Zhao Y; Du H; Guo X
    Front Oncol; 2021; 11():704336. PubMed ID: 34490104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances.
    Singh BH; Gulley JL
    Ther Adv Vaccines; 2014 Sep; 2(5):137-48. PubMed ID: 25177493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potentiating prostate cancer immunotherapy with oncolytic viruses.
    Lee P; Gujar S
    Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunodiagnostics and Immunotherapy Possibilities for Prostate Cancer.
    Schatten H
    Adv Exp Med Biol; 2018; 1096():185-194. PubMed ID: 30324354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapeutic advances in gastric cancer.
    Yoneda A; Kuroki T; Eguchi S
    Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future perspectives in cancer immunotherapy.
    Tsiatas M; Mountzios G; Curigliano G
    Ann Transl Med; 2016 Jul; 4(14):273. PubMed ID: 27563660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immuno-Oncology: Emerging Targets and Combination Therapies.
    Marshall HT; Djamgoz MBA
    Front Oncol; 2018; 8():315. PubMed ID: 30191140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The evolving landscape of immunotherapy in advanced prostate cancer.
    Patel VG; Oh WK
    Immunotherapy; 2019 Jul; 11(10):903-912. PubMed ID: 31161846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization.
    Reimers MA; Slane KE; Pachynski RK
    Curr Urol Rep; 2019 Sep; 20(10):64. PubMed ID: 31482315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for cholangiocarcinoma: a 2021 update.
    Charalampakis N; Papageorgiou G; Tsakatikas S; Fioretzaki R; Kole C; Kykalos S; Tolia M; Schizas D
    Immunotherapy; 2021 Sep; 13(13):1113-1134. PubMed ID: 34190581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.